

The Future of I-O: New Regimens and New Tumor Types

Invitation

Dear colleagues,

On behalf of Bristol-Myers Squibb, it is my pleasure to invite you to an industry satellite symposium entitled “The Future of I-O: New Regimens and New Tumor Types,” as part of the ESMO Symposium on Immuno-Oncology 2016 in Lausanne, Switzerland.

The ongoing development of novel agents that modulate immune checkpoint pathways in patients with cancer has led to very promising data, with many of these agents demonstrating activity across tumor types. These clinical data suggest the potential for achieving prolonged clinical benefit and provide the possibility for renewed hope in patients with advanced cancers.

In this symposium, we will discuss the role of the immune system in tumor types such as melanoma, lung cancer, renal cell carcinoma, and classical Hodgkin Lymphoma, while also highlighting recent advancements in the effort to extend the benefits of immuno-oncology to additional malignancies. There will be a special focus on combinations of immune checkpoint inhibitors in various tumor types.

We anticipate that the high levels of interaction and analysis provided by the symposium will inform and benefit your clinical practice, and look forward to welcoming you in Lausanne.

Olivier Michielin, MD, PhD
University of Lausanne, Switzerland
Meeting Chair

Program

- 13:30 | **Welcome and Introductions**
Olivier Michielin, MD, PhD
Switzerland
- 13:35 | **Impact of I-O on the Current Treatment Landscape**
Olivier Michielin, MD, PhD
Switzerland
- 13:50 | **Clinical Data Updates in Lung Cancer**
Solange Peters, MD, PhD
Switzerland
- 14:05 | **Future Considerations for I-O Therapies Across Tumor Types**
Jason Luke, MD, FACP
United States
- 14:20 | **Summary and Close Audience Q&A Full Panel**

Friday, 4 November 2016 | 13:30–14:30
SwissTech Convention Center
Auditorium A
Lausanne, Switzerland